Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;7(Suppl 4):S490-S497.
doi: 10.21037/tau.2018.04.08.

Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways

Eric Eidelman  1 , Hemantkumar Tripathi  1 , De-Xue Fu  1 , M Minhaj Siddiqui  1
Affiliations
Review

Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways

Eric Eidelman et al. Transl Androl Urol. 2018 Sep.

Abstract

Prostate cancer treatment is based on the stratification of disease as low-, intermediate- or high-risk. This stratification has been largely based on anatomic pathology of the disease, as well as through the use of prostate specific antigen (PSA). However, despite this stratification, there remains heterogeneity within the current classification schema. Utilizing a metabolic approach may help to further establish novel biomolecular markers of disease aggressiveness. These markers may eventually be useful in not only the diagnosis of disease but in creating tumor specific targeted therapy for improved clinical outcomes.

Keywords: Prostatic neoplasms; metabolic networks and pathways; metabolism; metabolomics; precision medicine; therapies, investigational.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2014 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2017.
    1. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing - GOV.UK. Public Health England. Available online: Https://www.gov.uk/government/publications/prostate-cancer-risk-manageme...
    1. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and psa testing patterns in relation to uspstf screening recommendations. JAMA 2015;314:2054-61. 10.1001/jama.2015.14905 - DOI - PubMed
    1. McDunn JE, Li Z, Adam KP, et al. Metabolomic signatures of aggressive prostate cancer. Prostate 2013;73:1547-60. 10.1002/pros.22704 - DOI - PubMed
    1. Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-Classification and therapy. Nat Rev Clin Oncol 2014;11: 308-23. 10.1038/nrclinonc.2014.68 - DOI - PMC - PubMed